SEC Form 4 · accession 0001127602-19-009956
CONMED Corp · CNMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Johonna Marie Pelletier
Officer — Treasurer and VP, Tax
Period of report
Mar 1, 2019
Accepted (ET)
Mar 5, 2019 · 4:50 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000816956
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 1, 2019 | M | 250 | $0.00 | A | 3,473 | D | |
| Common Stock | Mar 1, 2019 | F | 123 | $78.76 | D | 3,350 | D | |
| Common Stock | Mar 1, 2019 | M | 125 | $0.00 | A | 3,475 | D | |
| Common Stock | Mar 1, 2019 | F | 62 | $78.76 | D | 3,413 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options To Purchase Common StockF1 | $78.76 | Mar 1, 2019 | A | 13,500 | A | — | Mar 1, 2029 | Common Stock | 13,500 | 13,500 | D |
| Rsus (restricted Stock Units)F2 | $0.00 | Mar 1, 2019 | M | 250 | D | — | Feb 27, 2025 | Common Stock | 250 | 0 | D |
| Rsus (restricted Stock Units)F3 | $0.00 | Mar 1, 2019 | M | 125 | D | — | Mar 1, 2026 | Common Stock | 125 | 125 | D |
Explanation of responses
- F1The stock options were granted under the Company's 2018 Long-Term Incentive Plan and generally vest in equal amounts over a five year period
- F2Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 1999 Amended and Restated Long-Term Incentive Plan and generally vest in equal amounts (25%) over a four year period.
- F3Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2015 Amended and Restated Long-Term Incentive Plan and generally vest in equal amounts (25%) over a four year period.